FloBio

FloBio is a private Philadelphia-based medical diagnostics company developing a novel point-of-care hemostasis testing platform for emergency and critical care settings. Its technology uses a fluidic, microenvironment-mimicking assay to evaluate blood clotting function under physiologic flow conditions and to detect direct oral anticoagulants in real time at the bedside. The company is focused on helping clinicians rapidly assess bleeding and thrombotic risk and make more informed decisions about reversal agents and other interventions. FloBio has received FDA Breakthrough Device Designation for its bleeding risk diagnostic test and appears to be advancing as an in-vitro diagnostic platform company rather than a therapeutics developer.